Articles tagged with Kidney Cancer
Researchers developed a novel form of radioimmunotherapy that targets antigens associated with renal cell carcinoma. Patients receiving up to three doses show dramatic slowing of cancer growth and stabilization of their disease. The therapy, Lu-177-cG250, targets kidney tumors with high effectiveness for reducing cancer proliferation.
Researchers at Fox Chase Cancer Center discovered that a low lymphocyte count is a simple and effective prognostic indicator in patients with renal cell carcinoma. The study found that lower lymphocyte levels are associated with a higher tumor grade, pathologic tumor stage, presence of distant metastases, and lower overall survival rate.
Researchers at OHSU Knight Cancer Institute discovered a gene called Src that plays a key role in kidney cancer growth. This finding could lead to more effective treatments for patients who don't respond to current therapies. The study's authors are now initiating clinical trials to test how these tumors respond to existing FDA-approve...
Researchers identified a unique protein modification induced by fumarate hydratase deficiency in a rare type of cancer. This 'biological fingerprint' can be used as a biomarker to identify tumors caused by this mechanism, leading to early diagnosis and potential targeted treatments.
A study found that low lymphocyte counts before surgery are associated with poor prognosis, higher tumor grades, and lower overall survival rates. The researchers suggest that this test could help doctors individualize therapies and change clinical decisions.
Researchers from Fox Chase Cancer Center investigated the effectiveness of active surveillance in patients with small renal masses. They found that in select patients, active surveillance may be a viable option when surgery is risky due to poor health or advanced age.
The incidence of idiopathic pulmonary fibrosis (IPF) is increasing rapidly in the UK, with estimated annual diagnoses of 5,000 new cases. Researchers found a significant rise in IPF-related deaths, with more people dying from IPF than from certain types of cancer.
Researchers at UT Southwestern Medical Center have discovered genetic pathways that selectively starve kidney cancer cells. The study found that inactivating the von Hippel-Lindau gene can block cells from using oxygen to generate energy, forcing them to use alternative methods such as glycolysis.
Researchers have identified a frequently mutated gene, PBRM1, in one in three patients with the most common form of renal cancer. The gene is tied to two previously identified genes on chromosome 3 and plays a role in controlling cell growth and repairing DNA damage.
Researchers have identified a gene, PBRM1, that is mutated in one in three patients with clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. This discovery provides new insights into the biology of renal cancer and may lead to new therapeutic directions for treatment.
Researchers have developed a novel virus-based gene therapy for renal cell carcinoma, killing cancer cells both locally and distantly. The therapy combines Sorafenib with Ad.5/3-mda-7 adenovirus, which activates the MDA-7/IL-24 protein to stop tumor growth.
A recent study has raised concerns about the safety of certain plant-based antioxidants, including quercetin and ferulic acid. The research found that these antioxidants may aggravate or even cause kidney cancer in diabetic laboratory rats.
A study found that quercetin and ferulic acid aggravated kidney cancer in severely diabetic laboratory rats, raising concerns about their safety. The researchers recommend reevaluating the safety of plant-based antioxidants until further evidence is available.
A team of Fox Chase Cancer Center researchers identified an activation signal for the Aurora-A oncogene, a hyperactive enzyme driving tumor cell proliferation. The discovery may lead to new insights into how cell division is timed and potentially improve treatment options by combining AurA inhibitors with other drugs.
Radiofrequency ablation proved as effective as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment. The minimally invasive procedure showed superior preservation of kidney tissue, leading to improved quality of life and length of life for patients.
A new Mayo Clinic study found that complete removal of all tumors that spread can significantly improve prognosis for kidney cancer patients. Patients who underwent complete tumor removal had an average cancer-specific survival rate of 5 years, compared to just 1 year for those without metastatic tumors removed.
Researchers present studies demonstrating progress in using the R.E.N.A.L. Nephrometry Scoring system to standardize surgical decision-making and improve patient outcomes for patients with kidney cancers. The system captures anatomical features of renal masses, allowing for more accurate evaluation of treatment strategies.
A new diagnostic scan using 124I-girentuximab with PET/CT imaging can distinguish between aggressive and less aggressive kidney masses, helping to avoid unnecessary surgeries. The test has a sensitivity and specificity of 86% and 87%, respectively, making it a promising tool for personalized treatment strategies.
A Phase II trial found that sunitinib was not effective in patients with papillary renal cell carcinoma, highlighting the need for new therapies for this rare subtype of kidney cancer. The study suggests differences in response between clear- and non-clear cell subtypes.
Researchers at Mayo Clinic have identified a key gene called GATA3 that is silenced in common kidney cancer, promoting its development. The discovery suggests that a combination of agents may turn the gene back on, providing a much-needed therapy for difficult-to-treat kidney cancer.
Researchers at Mayo Clinic have discovered gene signatures that explain the biology of clear cell renal cell carcinoma (ccRCC), a common and difficult-to-treat kidney cancer. They identified master genes lost in ccRCC that likely drive its development, as well as stem cell-like properties that contribute to its resistance to treatment.
Elderly patients with localized kidney cancer may benefit from conservative care, such as observation or treatments that spare the noncancerous parts of their kidneys. The study found no significant difference in survival rates between those who had their entire kidney removed and those who received active monitoring.
A significant study found that no single immunosuppressive drug regimen increases the risk of cancer among kidney transplant patients. However, factors such as age and smoking history contribute to increased cancer risk.
A study finds that cancer risk in kidney transplant recipients is similar across different immunosuppressive medications, suggesting no single medication is to blame. Patient characteristics such as age and eye color are associated with increased cancer risk.
The EORTC 30904 study found that conservative surgery is not inferior to radical renal surgery or nephrectomy, with a slightly higher complication rate. Overall survival rates were shorter on the conservative arm for all randomized patients, but not different for RCC or clinically/pathologically eligible patients.
Researchers at Henry Ford Hospital found that patients with hepatitis C infection were nearly twice as likely to develop kidney cancer as those without the disease. The study, published in Cancer Epidemiology, Biomarkers & Prevention, suggests a higher risk for younger HCV-positive patients.
Researchers identified two proteins in urine that accurately reveal 90% of all kidney cancers, offering a promising diagnostic tool. The discovery could save lives and preserve kidney function by detecting the disease at an early stage.
A large case-control study found that men with higher occupational sunlight exposure had a reduced risk of kidney cancer. Vitamin D, metabolized in the kidneys, may play a role in preventing some cancers.
Van Andel Research Institute researchers found a way to reverse resistance to sunitinib, a treatment for clear cell renal cell carcinoma, by administering sunitinib and IL-8 neutralizing antibodies. This discovery may help predict patients' response to the treatment.
Researchers found that sorafenib therapy can reduce large kidney tumors by up to 40% prior to surgery, making patient recovery less challenging. The study's results suggest a promising new treatment option for patients with advanced kidney cancer.
A new study published in The Lancet found that combination therapy does not improve overall or progression-free survival compared to single therapy for renal cell carcinoma. However, the combined regimen may still benefit a small number of patients by producing long remissions.
A new study published in Journal of Clinical Oncology found that pazopanib slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54%. The drug targets multiple pathways within cancer cells, inhibiting blood vessel development. Common side effects include diarrhea, hypertension, and weight loss.
Researchers sequenced over 100 kidney cancer samples, identifying mutations in genes controlling gene expression and chromatin structure. The study reveals genetic complexity in ccRCC, providing insights into diagnosis and treatment options.
A study found sunitinib to be safe and well-tolerated in patients with brain metastases, poor performance status, and elderly age groups. Median progression-free and overall survival were 10.9 and 18.4 months respectively.
A recent study suggests that weight-loss surgery could be associated with reduced cancer risk in obese women, with a 42% decrease in first-time cancers over 10 years. However, the surgery had no effect on cancer incidence in men. The findings indicate that bariatric surgery may have broader benefits for women's cancer prevention.
A phase I trial found a two-drug combination of temsirolimus and bryostatin to be safe and active in patients with metastatic kidney cancer. The combination showed sustained responses in some patients, particularly those with rare forms of renal cell carcinoma that don't respond well to standard therapies.
A Canadian Cancer Society-funded study will investigate the risk of bladder and kidney cancer associated with environmental exposure to arsenic in drinking water. Dr Louise Parker's three-year research project aims to help policy-makers decide whether new approaches to water testing and treatment are needed.
A new study found that men with moderate kidney disease have a 39% increased risk of developing cancer compared to those with normal kidney function. The risk is highest for lung and urinary tract cancers, but not prostate cancer. Maintaining kidney function may help prevent cancer in the general population.
Researchers found that adult cystic nephroma and mixed epithelial and stromal tumors are genetically similar and should be considered the same disease entity. This discovery will help doctors accurately diagnose the disease in patients, leading to improved patient care.
A new robotic approach to surgically treat urothelial cancer of the kidney is proving to be effective, offering benefits such as less bleeding and scarring, shorter hospital stays, and faster recovery times. The minimally invasive surgery allows for the preservation of kidney function in patients with stage 3 chronic kidney disease.
Patients undergoing robotic-assisted partial nephrectomy experience improved outcomes, with faster recovery times and lower blood loss. This minimally invasive approach enables earlier return to normal activity, reducing the delay in treatment for patients with kidney cancer.
A study by Fox Chase Cancer Center found that patients with Medicare are less likely to undergo kidney-sparing surgery for renal cell carcinoma compared to those with private insurance. This disparity affects the quality of care and has implications for healthcare reform.
The European Association of Urology has released new clinical guidelines for kidney cancer treatment, emphasizing the use of targeted agents and nephron-sparing surgery. The guidelines recommend first-line therapies for low- and intermediate-risk patients, as well as second-line options for high-risk patients.
A new minimally invasive treatment, cryoablation, is nearly 100% effective in destroying localized kidney tumors. This procedure is a viable option for patients with small or large tumors and offers quicker recovery and minimal limitation on regular activities.
Researchers found that ozone treatment can relieve herniated disk pain by reducing disk volume, resulting in improved pain and function outcomes. The treatment's complication rate is less than 0.1 percent and recovery time is significantly shorter compared to surgery.
The Society of Interventional Radiology will present research on treatments for kidney, prostate, bone cancer, herniated disks, and more at its 34th Annual Scientific Meeting. The meeting will showcase innovative interventional radiology studies and treatments.
Researchers have identified a diagnostic biomarker SPOP that can accurately detect clear cell renal cell carcinoma, the most common type of kidney cancer. The study found that 99% of clear cell RCC samples showed elevated SPOP levels, making it a highly sensitive and specific diagnostic tool.
Researchers at UC Davis Cancer Center have identified three compounds that can help make chemotherapy for kidney cancer more effective by blocking the repair mechanism of a key cancer gene. These findings offer hope for patients who currently face limited treatment options and many side effects.
Researchers analyzed data from 13 prospective studies involving over half a million participants and found no link between fat, protein, or meat intake and kidney cancer. The study's findings suggest that the cause of increasing kidney cancer incidence worldwide remains unclear.
A meta-analysis of 15 randomized controlled trials found that bevacizumab increases the risk of venous thromboembolism by 33% compared to controls. The risk is highest for patients with colorectal cancer, with an incidence rate of 19.1%.
Research identified three genes linked to fat processing that could raise kidney cancer risk, according to a study presented at the American Association for Cancer Research. Variants of nitric oxide synthase 2A and prostaglandin-endoperoxide 2 were found to increase risk, while apolipoprotein E1 was associated with reduced risk.
A landmark UCLA study reveals that tailored treatment approaches can significantly improve kidney cancer patient survival rates, with some patients experiencing excellent outcomes of up to 97%. The study identified subsets of patients who require different levels of treatment, including surgery and targeted therapies.
A subset analysis of a randomized trial found that older patients with renal cell carcinoma derive similar clinical benefits from sorafenib therapy as younger patients, including improved progression-free survival and quality of life. The treatment was well-tolerated regardless of age, with manageable side effects.
A study of 1,500 kidney cancer patients suggests that tissue-sparing surgery may improve overall survival in patients with reduced kidney function. The finding highlights the underuse of this option and raises concerns about the potential harm of removing healthy kidney tissue.
Researchers create genetically modified mice with a switch to turn on and off disease-typical proteins in renal tissue. The model simulates the natural course of disease development and healing processes, allowing for better investigation of kidney diseases.
A randomized controlled phase III trial found that everolimus significantly improves progression-free survival compared to placebo in patients with metastatic kidney cancer who have failed on sunitinib and sorafenib. The study also reported common adverse events, including stomatitis and fatigue.
Researchers at Stanford University School of Medicine have identified a molecule that selectively kills kidney cancer cells without harming healthy ones. This breakthrough finding could lead to the development of a life-saving treatment that preserves patients' kidneys.
Scientists discovered a compound, STF-62247, that induces autophagy in VHL-deficient kidney cancer cells, leading to selective cell death. This finding represents a new direction for targeted therapy against kidney cancer.
A new vitespen vaccine was tested on post-operative kidney cancer patients, but showed no significant improvement in recurrence-free survival. In early stage disease, patients receiving the vaccine had a lower risk of recurrence, but this finding requires further validation.
A new nomogram model predicts the probability of renal cancer recurrence 12 years after initial treatment, using tumor and patient characteristics to maximize predictive accuracy. The model helps clinicians counsel patients and customize treatment recommendations for individual patients.